At the time of writing, Spyre Therapeutics Inc [SYRE] stock is trading at $18.65, down -4.31%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SYRE shares have gain 3.96% over the last week, with a monthly amount drifted -21.84%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Spyre Therapeutics Inc [NASDAQ: SYRE] stock has seen the most recent analyst activity on September 04, 2024, when Wedbush initiated its Outperform rating and assigned the stock a price target of $45. On May 02, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $50 on the stock. Wells Fargo upgraded its rating to a Overweight and increased its price target to $35 on March 01, 2024. BTIG Research initiated its recommendation with a Buy and recommended $32 as its price target on December 20, 2023. Jefferies started tracking with a Buy rating for this stock on December 11, 2023, and assigned it a price target of $31. In a note dated December 11, 2023, Guggenheim initiated an Buy rating and provided a target price of $44 on this stock.
For the past year, the stock price of Spyre Therapeutics Inc fluctuated between $17.24 and $47.97. Currently, Wall Street analysts expect the stock to reach $53.67 within the next 12 months. Spyre Therapeutics Inc [NASDAQ: SYRE] shares were valued at $18.65 at the most recent close of the market. An investor can expect a potential return of 187.77% based on the average SYRE price forecast.
Analyzing the SYRE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.61 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.97 points at the first support level, and at 17.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.53, and for the 2nd resistance point, it is at 20.42.
Ratios To Look Out For
It is important to note that Spyre Therapeutics Inc [NASDAQ:SYRE] has a current ratio of 11.26. Further, the Quick Ratio stands at 11.26, while the Cash Ratio is 1.65.
Transactions by insiders
Recent insider trading involved Albers Jeffrey W., Director, that happened on Nov 06 ’24 when 6700.0 shares were sold. Director, Albers Jeffrey W. completed a deal on Oct 25 ’24 to sell 300.0 shares. Meanwhile, Director SESSIONS, LLC bought 7000.0 shares on Oct 25 ’24.
